Management of Hypercalcemia
Introduction to Hypercalcemia Management
- Hypercalcemia management involves discontinuation of hydrochlorothiazide, which can cause hypercalcemia by reducing urinary calcium excretion, according to the American Society of Nephrology 1
Medication Management
- Active vitamin D (calcitriol) therapy should be started with low doses (0.25-0.5 μg daily) and titrated based on calcium response in patients with low calcium levels despite supplementation, as recommended by the American Journal of Kidney Diseases 2
- Total elemental calcium intake should not exceed 2,000 mg/day in CKD patients, with a target total daily calcium intake of 1500 mg, and supplemental calcium added if dietary calcium is inadequate, as recommended by the National Kidney Foundation 2, 3
- Maintain the calcium-phosphorus product below 55 mg²/dL² to reduce calcification risk, as recommended by the National Kidney Foundation 2
- Supplement with native vitamin D (cholecalciferol or ergocalciferol) for patients with 25-OH vitamin D levels <20 ng/mL, as suggested by the Nature Reviews Nephrology guidelines 4
- Target 25-OH vitamin D levels should be greater than 20 ng/mL (50 nmol/L), as recommended by the National Kidney Foundation 4
Phosphate Management
- Phosphate restriction (800-1000 mg/day) and phosphate binders may be used for patients with CKD, as recommended by the American Journal of Kidney Diseases 2
- Avoid prolonged use of aluminum-based binders due to risk of aluminum toxicity, as recommended by the National Kidney Foundation 2
Parathyroid Hormone (PTH) Management
- Evaluate PTH levels, with target levels:
| CKD Stage | Target PTH Level |
|---|---|
| CKD G3 | <70 pg/mL |
| CKD G4 | <110 pg/mL |
| CKD G5 | <300 pg/mL |
| CKD G5D | 150-600 pg/mL |
- Active vitamin D analogs, such as calcitriol, alfacalcidol, and paricalcitol, may be used for persistent elevation in patients with CKD, with treatment approach adjusted based on PTH levels:
| PTH Level | Treatment Approach |
|---|---|
| Mildly elevated | Optimize calcium and vitamin D levels |
| 150-300 pg/mL | Maintain current therapy |
| 300-500 pg/mL | Increase vitamin D sterols, adjust phosphate binders |
| 500-800 pg/mL | Higher doses of vitamin D sterols, consider adding cinacalcet |
| >800 pg/mL | Consider parathyroidectomy if medical therapy fails, as recommended by the guideline society [2] |
Surgical Management
- Parathyroidectomy is indicated for symptomatic patients, including those with kidney stones, and should be considered for renal transplant candidates with secondary hyperparathyroidism, according to the American Society of Transplantation 8
- Parathyroidectomy may be considered in cases of persistent hypercalcemic hyperparathyroidism despite optimized active vitamin D and cinacalcet therapy, according to the National Kidney Foundation and the American College of Radiology 1, 9
Monitoring and Follow-up
- Monitor serum calcium, phosphate, ALP, and PTH levels regularly, and adjust vitamin D dosage based on ALP levels, PTH levels, and urinary calcium excretion, as recommended by the National Kidney Foundation 1
- Monitor calcium, phosphorus, and PTH levels regularly, with frequency depending on CKD stage:
| CKD Stage | Calcium & Phosphorus | PTH |
|---|---|---|
| Stage 3 | Every 6-12 months | Every 6-12 months |
| Stage 4 | Every 3-6 months | Every 3-6 months |
| Stage 5 | Every 1-3 months | Every 1-3 months |
| Dialysis | Monthly | Monthly |
- Regular assessment for bone disease may be needed in patients with fractures or risk factors for osteoporosis, as recommended by the National Kidney Foundation 2
- Consideration of cinacalcet for severe hyperparathyroidism that develops despite normal calcium levels is recommended, with caution due to the risk of hypocalcemia and QT interval prolongation 4